Abstract
This cohort study compares the delays in tumor necrosis factor inhibitor (TNFi) initiation because of insurance among children enrolled in public and private insurance plans.
MeSH terms
-
Antirheumatic Agents* / therapeutic use
-
Arthritis, Juvenile* / drug therapy
-
Arthritis, Juvenile* / pathology
-
Child
-
Humans
-
Insurance*
-
Tumor Necrosis Factor Inhibitors / therapeutic use
-
Tumor Necrosis Factor-alpha
Substances
-
Antirheumatic Agents
-
Tumor Necrosis Factor Inhibitors
-
Tumor Necrosis Factor-alpha